









Markets
/
Stocks
/
nasdaq-lvtx
/

LAVA Therapeutics NV

LVTX

1.615USD

-0.010-0.62%

Close 11/05, 16:00（ET）Quotes delayed by 15 min

42.48MMarket Cap

LossP/E TTM



LAVA Therapeutics NV

1.615

-0.010-0.62%

Overview Company Financials Analysis

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

Overview

Company

Financials

Analysis

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score of LAVA Therapeutics NV

Currency: USD Updated: 2025-11-05

Key Insights

The company's fundamentals are relatively very healthy. Its valuation is considered fairly valued,and institutional recognition is very high. Over the past 30 days, multiple analysts have rated the company as a Hold. Despite an average stock market performance, the company shows strong fundamentals and technicals. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

LAVA Therapeutics NV's Score

Industry at a Glance

Industry Ranking

98 / 407

Overall Ranking

224 / 4616

Industry

Biotechnology & Medical Research

Support & Resistance

No Data

Score Analysis

Current score

Previous score

Analyst Rating

Based on 2 analysts

Hold

Current Rating

1.370

Target Price

-15.69%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

LAVA Therapeutics NV Highlights

StrengthsRisks

LAVA Therapeutics NV, formerly known as Lava Therapeutics BV, is a provider of biotechnology research and development services based in the Netherlands. The Company focuses of developing next generation Vdelta T cell engaging bispecific antibodies to fight cancer.

Growing

The company is in a growing phase, with the latest annual income totaling USD 11.98M.

Fairly Valued

The company’s latest PE is -1.53, at a medium 3-year percentile range.

Institutional Selling

The latest institutional holdings are 7.48M shares, decreasing 38.60% quarter-over-quarter.

Higher Market Activity

The company has more investor interest, with a 20-day turnover ratio of -0.49.

Financial Health

Currency: USD Updated: 2025-11-05

The company's current financial score is 7.58, which is higher than the Biotechnology & Medical Research industry's average of 6.92. Its financial status is robust, and its operating efficiency is low.

Score

Industry at a Glance

Previous score

7.58

Change



Financials

10.00

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

No Data



Quality of Earnings

10.00

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

No Data



Operational Efficiency

2.67

Key Metrics

Cash flow from operating activities

Income after tax

No Data



Growth Potential

8.11

Key Metrics

Cash flow from operating activities

Total revenue

No Data



Shareholder Returns

7.10

Key Metrics

Free cash flow

No Data

LAVA Therapeutics NV's Company Valuation

Currency: USD Updated: 2025-11-05

The company’s current valuation score is 7.87, which is higher than the Biotechnology & Medical Research industry's average of 7.05. Its current P/E ratio is -1.53, which is -60.18% below the recent high of -0.61 and -110.98% above the recent low of -3.23.

Score

Industry at a Glance

Previous score

7.87

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 98/407

No Data

Earnings Forecast

Currency: USD Updated: 2025-11-05

The company’s current earnings forecast score is 6.00, which is lower than the Biotechnology & Medical Research industry's average of 8.00. The average price target for LAVA Therapeutics NV is 1.37, with a high of 1.50 and a low of 1.24.

Score

Industry at a Glance

Previous score

6.00

Change

Support & Resistance

No Data

Analyst Rating

Based on 2 analysts

Hold

Current Rating

1.370

Target Price

-15.69%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

521

Total

Median

Average

Company name

Ratings

Analysts

LAVA Therapeutics NV

LVTX

CRISPR Therapeutics AG

CRSP

Intellia Therapeutics Inc

NTLA

IQVIA Holdings Inc

IQV

Ionis Pharmaceuticals Inc

IONS

argenx SE

ARGX

...

104

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

No Data

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2025-11-05

The company’s current price momentum score is 8.34, which is higher than the Biotechnology & Medical Research industry's average of 6.49. Sideways: Currently, the stock price is trading between the resistance level at 1.69 and the support level at 1.49, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

8.20

Change

0.14

Support & Resistance

No Data

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(3)

Neutral(2)

Buy(1)

Indicators

Value

Direction

MACD(12,26,9)

0.010

Buy

RSI(14)

57.043

Neutral

STOCH(KDJ)(9,3,3)

71.075

Sell

ATR(14)

0.054

Low Volatility

CCI(14)

45.123

Neutral

Williams %R

12.500

Overbought

TRIX(12,20)

0.184

Sell

StochRSI(14)

0.000

Sell

Moving Average

Sell(2)

Neutral(0)

Buy(4)

Indicators

Value

Direction

MA5

1.625

Sell

MA10

1.617

Sell

MA20

1.573

Buy

MA50

1.565

Buy

MA100

1.496

Buy

MA200

1.351

Buy

Institutional Confidence

Currency: USD Updated: 2025-11-05

Score

Industry at a Glance

Previous score

3.00

Change

Institutional Shareholding

No Data

Shareholder Activity

Name

Shares Held

Chg %

Shay Capital LLC

2.60M

Redmile Group, LLC

2.07M

BML Capital Management LLC

1.97M

+0.51%

Sanofi SA

1.92M

Merck & Co Inc

1.15M

Cooperatieve Gilde Healthcare IV UA

5.42M

Bruce & Company, Inc.

521.87K

Hurly (Stephen A.)

151.80K

+2935.98%

Powell (Fred M)

100.26K

+54.24%

PNC Investments LLC

65.00K

Risk Assessment

Currency: USD Updated: 2025-11-05

The company’s current risk assessment score is 3.39, which is lower than the Biotechnology & Medical Research industry's average of 3.47. The company's beta value is 0.50. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets.